Insider Transactions in Q2 2021 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2021
|
Steven C Gilman |
SELL
Open market or private sale
|
Direct |
4,567
-8.69%
|
$13,701
$3.32 P/Share
|
|
Jun 02
2021
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
13,700
+20.67%
|
-
|
|
Jun 02
2021
|
Michael Thomas Heffernan |
BUY
Grant, award, or other acquisition
|
Direct |
13,700
+22.0%
|
-
|
|
Jun 02
2021
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
13,700
+13.07%
|
-
|
|
Jun 02
2021
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
13,700
+20.75%
|
-
|
|
Jun 02
2021
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
13,700
+21.0%
|
-
|
|
Jun 02
2021
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
13,700
+36.36%
|
-
|
|
Apr 01
2021
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,081
-0.63%
|
$3,243
$3.4 P/Share
|
|
Apr 01
2021
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
4,109
-0.36%
|
$12,327
$3.4 P/Share
|
|
Apr 01
2021
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,211
-0.45%
|
$3,633
$3.4 P/Share
|
|
Apr 01
2021
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,060
-0.39%
|
$3,180
$3.4 P/Share
|
|
Apr 01
2021
|
David A Spellman SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
790
-1.02%
|
$2,370
$3.4 P/Share
|
|
Apr 01
2021
|
Dell Faulkingham SVP, CCO |
SELL
Open market or private sale
|
Direct |
952
-0.69%
|
$2,856
$3.4 P/Share
|